Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2020-2021)

Cancer metastasis involves the spread of cancer cells from one organ to another and is thex000D
cause of 90% of cancer-related deaths. Current therapies fail to block metastasis effectively,x000D
and our invention of novel actin-targeted ADCs will address this unmet need. Dynamicx000D
modifications of the actin cytoskeleton are essential for cancer cells to breakthrough tissuex000D
and blood vessel barriers during metastasis. Targeting this "actin addiction" is the goal of thisx000D
project, which is built on our detailed knowledge of potent natural inhibitors of actin. Ourx000D
multidisciplinary team has designed, synthesized and tested novel actin toxin analogs thatx000D
block growth, motility and invasion of metastatic cancer cells in vitro. Currently, we are linkingx000D
these to antibodies used in oncology, and will test these novel ADCs in preclinical mousex000D
models of metastatic cancers relevant to each clinically used antibody. These studies willx000D
measure effects of our ADCs on tumour progression and metastasis.